Is Pegasys Approved for Hepatitis C and HIV Co-Infection?
Yes, Pegasys (peginterferon alfa-2a) is approved for treating chronic hepatitis C virus (HCV) in patients co-infected with HIV. The FDA approved this use in 2002, based on clinical trials showing it effectively reduces HCV viral load when combined with ribavirin. Treatment typically lasts 48 weeks for genotype 1 and 24 weeks for other genotypes, with monitoring for anemia and psychiatric effects due to heightened risks in co-infected patients.[1][2]
How Does Treatment Work in Co-Infection?
Pegasys, a pegylated interferon injected weekly, boosts the immune response against HCV while ribavirin prevents viral replication. In HIV/HCV co-infection, it achieves sustained virologic response (SVR) rates of 30-40% for genotype 1, lower than in HCV mono-infection due to faster liver fibrosis. HAART therapy is continued alongside to manage HIV, avoiding drug interactions like those with didanosine.[1][3]
What Do Clinical Studies Show?
Phase III trials (e.g., APRICOT study, n=868) reported SVR rates of 44% overall in co-infected patients on Pegasys plus ribavirin, versus 20% with standard interferon. Genotype non-1 patients responded better (62% SVR). Liver decompensation occurred in 7% of cirrhotics, emphasizing need for baseline assessment.[2][4]
Why Is It Less Used Today?
Direct-acting antivirals (DAAs) like sofosbuvir/velpatasvir cure >95% of HCV cases in co-infected patients with 8-12 week oral regimens, sidelining Pegasys since 2014-2016 approvals. Guidelines (AASLD/IDSA, EASL) now recommend DAAs first-line; Pegasys is reserved for DAA failures or limited-access settings.[3][5]
Common Side Effects in Co-Infected Patients
Flu-like symptoms (80%), fatigue (60%), and neutropenia (25%) are frequent. Co-infection raises risks of thrombocytopenia, depression (20%), and ribavirin-induced hemolytic anemia, requiring dose adjustments and growth factors. Discontinuation rates hit 20-30%.[1][4]
Who Makes Pegasys and Availability?
Roche/Genentech manufactures Pegasys. Patents expired in the US by 2020, but it's available generically in some markets. Check DrugPatentWatch.com for expiration details and generics.[6]
Sources
[1]: FDA Label for Pegasys
[2]: NEJM: Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Infected Patients (APRICOT)
[3]: AASLD/IDSA HCV Guidance 2023
[4]: Clinical Infectious Diseases: Treatment of HCV/HIV Co-Infection
[5]: EASL Recommendations on HCV
[6]: DrugPatentWatch.com: Pegasys Patents